Abstract:Abstract Background Ustekinumab (UST), an anti-IL12/23p40 monoclonal antibody, is now widely used for ulcerative colitis (UC). Meanwhile, there are no established models to predict the efficacy of UST for UC. We previously demonstrated that the machine-leaning approach was useful for finding predictors and developing a prediction tool in vedolizumab (VDZ) treatment for UC (Miyoshi et al. Sci. Rep. 2021). In this study, we aimed to develop a new prediction model for UST in patients with UC. Methods UC patients who started UST as a remission induction therapy in Kyorin University Hospital were enrolled as the training cohort (Cohort 1), and at Toho University Sakura Medical Center were enrolled as the test cohort (Cohort 2). Clinical information of 44 items including age, sex, past/concomitant therapy for UC, clinical and endoscopic activity for UC, blood sample, and so on, in week 0, and clinical activity for UC in week 22 were collected. The outcome was defined as steroid-free clinical remission (SFCR) in week 22. Clinical remission was defined as the Lichtiger index (LI) of four or lower. Patients who terminated UST or needed surgery before week 22 were regarded as not achieving SFCR. Random Forest was used for the clinical data in Cohort 1 to identify the promising predictors to achieve SFCR in week 22. Prediction models were developed with these predictors and their prediction ability was validated in Cohort 2. Results 25 patients (SFCR/non-SFCR=13/12 patients) and 46 patients (SFCR/non-SFCR=27/19 patients) were enrolled as Cohort 1 and Cohort 2, respectively, in this study. First, we examined if a VDZ prediction model that we previously reported could work for predicting the UST efficacy. In Cohort 1, the model showed a positive predictive value (PPV) of 56.3% and a negative predictive value (NPV) of 62.5%. This supports the notion that a prediction model for UST should be different from that for VDZ. From the 44 clinical information, 10 clinical features with the highest contribution to SFCR with UST were detected in Cohort 1. These clinical features included serum albumin, monocyte fraction, height, MCV, total protein, LI, white blood cell count, MCHC, partial Mayo score, and CRP (Figure 1). With these 10 clinical features, the seven prediction models for UST were developed using different algorithms. These models were applied to Cohort 2 to validate the prediction ability. The model that showed the best prediction ability was a support-vector machine polynomial model with PPV 68.8% and NPV 71.4%, respectively. Conclusion We developed a new prediction model for the middle-term efficacy of UST in patients with UC. Further studies are needed to develop a prediction model for each molecular-targeted drug.

Predicting ulcerative colitis relapse in clinical remission with fecal immunochemical occult blood test or prostaglandin E-major urinary metabolite

Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis

Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker

Prostaglandin E-Major Urinary Metabolite as a Biomarker for Inflammation in Ulcerative Colitis: Prostaglandins Revisited

Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores.

Fecal Calprotectin in Predicting Relapse of Inflammatory Bowel Diseases: A Meta-Analysis of Prospective Studies

Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis

P282 High Correlation Between Fecal Immunochemical Test and Fecal Calprotectin for the Evaluation of Activity in Inflammatory Bowel Disease

P412 Faecal Calprotectin as a predictor of endoscopic and histologic remission in patients with Ulcerative Colitis

Risk factors for clinical relapse in patients with ulcerative colitis who are in clinical remission but with endoscopic activity

A New Risk Prediction Model for Detecting Endoscopic Activity of Ulcerative Colitis.

P576 Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy

Exploring Predictive Biomarkers of Relapse in Ulcerative Colitis: A Proteomics Approach

Importance of rectal over colon status in ulcerative colitis remission: the role of microinflammation and mucosal barrier dysfunction in relapse

Research about the Diagnostic and Predictive Value of Fecal Calprotectin in Ulcerative Colitis

Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan

Validation of rapid fecal calprotectin assay using particle enhanced turbidimetric immunoassay for inflammatory bowel disease

Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform–Infrared Spectroscopy Coupled with Machine Learning Algorithms

P1085 Machine learning to predict the efficacy of ustekinumab for ulcerative colitis

The value of fecal calprotectin in predicting endoscopic activity and severity of ulcerative colitis

P295 Early sonographic improvement predicts the middle-term efficacy of molecular-targeted medications for Ulcerative Colitis